CD40 agonists combined with anti-PD-1 have demonstrated enhanced DC maturation, increased tumor T-cell infiltration, and good antitumor efficacy (Ma et al., 2019; Diggs et al., 2021). The gene discussed is PDCD1; the disease is neoplasm.